Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

NCT03724968 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Loss of funding

Conditions

Metastatic Melanoma
Advanced Melanoma
Metastatic Melanoma Stratified by MHC-II Expression

Interventions

DRUG: Nivolumab
DRUG: Relatlimab
DRUG: Ipilimumab

Sponsor

Elizabeth Davis

Collaborators

[object Object]